Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Lamivudine + peginterferon alfa-2b is a combination therapy used primarily in the treatment of chronic hepatitis B virus (HBV) infection. Lamivudine is a synthetic nucleoside analogue that acts as a nucleoside reverse transcriptase inhibitor (NRTI), inhibiting viral DNA synthesis by incorporating into viral DNA and causing chain termination. Peginterferon alfa-2b is a pegylated recombinant interferon that binds to type 1 interferon receptors, activating the JAK/STAT pathway and inducing antiviral gene expression. The combination has been studied for both HBeAg-positive and HBeAg-negative chronic hepatitis B, but evidence suggests it does not provide superior efficacy compared to peginterferon alfa-2b monotherapy[4][5]. Both drugs are also individually approved for other indications: lamivudine for HIV and HBV, and peginterferon alfa-2b for hepatitis C and melanoma[1][6][7].
- Other names
- 3TCPEG-Intron
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on lamivudine + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + peginterferon alfa-2b.